产品编号 :
Cas No. :
| 包装规格 | 纯度 | 目录价 | 会员专享价 | 库存 | 数量 |
|---|---|---|---|---|---|
| 25mg | 95% | 询价 | |||
| 50mg | 95% | 询价 | |||
| 100mg | 95% | 询价 | |||
| 250mg | 95% | 询价 | |||
| 1g | 95% | 询价 |
| 包装规格 | 纯度 | 目录价 | 会员专享价 | 库存 | 数量 |
|---|---|---|---|---|---|
| 25mg | 95% | 询价 | |||
| 50mg | 95% | 询价 | |||
| 100mg | 95% | 询价 | |||
| 250mg | 95% | 询价 | |||
| 1g | 95% | 询价 |
CAS No. |
2227366-51-8 |
|---|---|
中文名称 |
道古霉素盐酸盐 |
英文名称 |
Dalbavancin hydrochloride |
别名 |
DTXSID001027643 |
标准英文名 |
(2S,3S,4R,5R,6S)-6-(((3S,14R,17R,33R,34S,37S,47R,49aR)-5,30-dichloro-37-((3-(dimethylamino)propyl)carbamoyl)-6,11,33,39,43-pentahydroxy-14-(methylamino)-2,15,35,49,50,58-hexaoxo-41-(((2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-2,3,15,16,17,18,34,35,36,37,47,48,49,49a-tetradecahydro-1H,14H,33H-3,17:34,47-bis(epiminomethano)-10,13:19,22:29,32-trietheno-4,8:24,27:42,46-tri(metheno)benzo[14,15][1]oxa[7,17]diazacyclotetracosino[4,5-d][1,14]dioxa[6,21]diazacycloheptacosin-55-yl)oxy)-3,4-dihydroxy-5-(10-methylundecanamido)tetrahydro-2H-pyran-2-carboxylic acid hydrochloride |
分子式 |
C88H101Cl3N10O28 |
分子量 |
1853.18 |
精确分子量 |
1850.59 |
SMILES |
CN[C@H]1C(=O)N[C@@H]2CC3=CC=C(C=C3)OC3=C(O[C@@H]4O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]4NC(=O)CCCCCCCCC(C)C)C4=CC(=C3)[C@@H](NC(=O)[C@@H](NC2=O)C2=C(Cl)C(O)=CC(=C2)OC2=CC=C1C=C2O)C(=O)N[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)NCCCN(C)C)C2=CC(O)=CC(O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]3O)=C2C2=C(O)C=CC1=C2)[C@H](O)C1=CC=C(O4)C(Cl)=C1.Cl |
标准SMILES |
Cl.CC(C)CCCCCCCCC(=O)N[C@H]1[C@@H](O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O)OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@@H]1NC(=O)[C@H](NC(=O)[C@@H]3NC(=O)[C@H]3NC(=O)[C@@H](CC4=CC=C(C=C4)O2)NC(=O)[C@H](NC)C2=CC=C(OC4=CC3=C(Cl)C(O)=C4)C(O)=C2)C2C=CC(O)=C(C=2)C2=C(C=C(O)C=C2[C@H](NC1=O)C(=O)NCCCN(C)C)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O |
用途 |
Dalbavancin hydrochloride is developed for the treatment of complicated skin and skin structure infections (cSSSIs), predominantly those caused by methicillin-resistant Staphylococcus aureus (MRSA) and β-hemolytic streptococci; it exhibits potent in vitro bactericidal activity against Gram-positive pathogens including S. aureus (MRSA), vancomycin-intermediate S. aureus (VISA), and non-VanA strains of vancomycin-resistant enterococci (VRE); it is also effective in vivo against Bacillus anthracis, showing 80–100% survival rates in murine models of anthrax infection. |
InChIKey |
VVZGNSSWZDAHSJ-AXKGEONOSA-N |
|
|
评论 |
|---|